Scientific Opinion on the substantiation of health claims related to conjugated linoleic acid (CLA) isomers and contribution to the maintenance or achievement of a normal body weight (ID 686, 726, 1516, 1518, 2892, 3165), increase in lean body mass (ID 498, 731), increase in insulin sensitivity (ID 1517), protection of DNA, proteins and lipids from oxidative damage (ID 564, 1937), and contribution to immune defences by stimulation of production of protective antibodies in response to vaccination (ID 687, 1519) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

Conjugated linoleic acid (CLA), isomers c9, t11 and t10, c12, body weight, lean body mass, insulin sensitivity, immune defences, pro-inflammatory, anti-inflammatory cytokines, health claims
First published in the EFSA Journal
19 October 2010
10 September 2010
Scientific Opinion

No abstract available

Panel members at the time of adoption
Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen.
Panel on Dietetic Products, Nutrition and Allergies
nda [at]
EFSA Journal 2010;8(10):1794 [26 pp.].
On request from
European Commission